Veriheal

MARCH 20, 2023

Using psilocybin in small doses, or microdosing, has been shown to aid in the treatment of various mental health issues, including anxiety, depression, PTSD, and obsessive-compulsive disorder. Smith cited results from clinical trials showing that MDMA holds promise in the treatment of PTSD. Minnesota Rep. Missouri Rep.

Clinical Trials 98

Clinical Trials Therapy Decriminalization Treatment 98

Cannabis Law Report

JUNE 14, 2022

Ketamine is already registered for the treatment of depression and in 2023, the FDA might approve an MDMA assisted therapy for PTSD. There are multiple clinical centers doing research with psychedelics in Europe and, inevitably, regulatory approvals in Europe will follow. Ahead of the launch, PAREA Chair Prof.

Access 52

Access Therapy Clinical Trials Treatment 52

Cannabis Law Report

NOVEMBER 23, 2021

London, UK – 23 November 2021 COMPASS Pathways plc a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fifth patent by the US Patent and Trademark Office. PRESS RELEASE.

Clinical Trials 52

Clinical Trials Therapy Research and Development Media 52

Cannabis Law Report

AUGUST 17, 2021

Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. RADNOR, Pa.–(BUSINESS Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

OCTOBER 5, 2021

Systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of mental health conditions. 30 September 2021. On 5 August 2021, the TGA announced that an Independent Expert Panel had been established to undertake the review. The review excludes pre-clinical trials (i.e.

Treatment 52

Treatment Conditions Medicine Clinical Trials 52

Cannabis Law Report

DECEMBER 1, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. Date: December 2, 2021. Dates: December 8-9, 2021. Registration: Click here.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

SpeedWeed

SEPTEMBER 17, 2021

The funding will allow MAPS Public Benefit Corporation (MAPS PBC) to activate a team to evaluate the scope of the lack of resources needed for TBI treatment. . Data collected from MAPS-sponsored Phase 3 clinical trials suggests that MDMA-assisted therapy appears promising in the treatment of TBI.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Cannabis Law Report

JUNE 21, 2021

In the medical cannabis industry, mostly due to the plant’s long history of prohibition, there is a decided lack of data regarding the use and efficacy of cannabis as a treatment for a wide variety of indications. The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain. RYAH Group Inc.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

APRIL 2, 2022

a leader in specialized ibogaine treatments for substance use disorder based in Sao Paolo, Brazil (the “Ibogaine Group”). In December 2021, Novamind announced a strategic investment and advisory agreement with Bienstar.

Clinical Trials 52

Clinical Trials Research and Development Medicine Therapy 52

Cannabis Law Report

MARCH 23, 2022

Psychedelic medicine could provide much needed treatment options for some mental health and neurological disorders in the near future. However, our drug laws impede research and deny patients access to these highly effective medicines. There are a number of differences between PAP and current treatment approaches.

Clinical Trials 52

Clinical Trials Treatment Medicine Access 52

Cannabis Law Report

MAY 10, 2022

Anxiety and sleep disorders were some reasons given for prescriptions despite lack of evidence for cannabis treatment, researchers find. Queensland was the source of 51% of prescriptions between 2016 and 2021. We are aware of clinical trials in that space, but not strong evidence.”. The Guardian writes.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Cannabis Law Report

DECEMBER 9, 2021

Phil Wolfson’s Ketamine Research Foundation, in support of their research into the awareness, understanding, and potential of psychedelics for the treatment of mental health disorders. Nue Life launched its proprietary nue.app on November 8 to increase access to psychedelic treatment as a catalyst for lasting change.

Research and Development 52

Research and Development Therapy Clinical Trials Treatment 52

Cannabis Law Report

NOVEMBER 7, 2021

The committee has been formed to expand the company’s pharmaceutical expertise and accelerate R&D, product development and clinical trials ahead of a potential NASDAQ listing. The committee will also enable CPH to accelerate R&D, product development and other clinical trials ahead of its potential NASDAQ listing.

Medicine 52

Medicine Clinical Trials Research and Development Pharmaceutical 52

Cannabis Law Report

JULY 6, 2021

London, UK – 5 July 2021. By combining our strengths in biomedical research, clinical trials, clinical care, translational science, training, and digital innovation, we can create a world-class centre of excellence in mental health.”. George Goldsmith, CEO and Co?founder,

Research and Development 98

Research and Development Clinical Trials Therapy Patients 98

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

DECEMBER 21, 2021

This UK-based company caught our attention in 2021 for its team of renowned psychedelic researchers, including chief research officer Professor David Nutt, chief medical officer Dr. Ben Sessa, and head of ketamine psychotherapy Dr. Celia Morgan, as well as its unique studies into ketamine treatment for addiction and gambling addiction.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Importantly, control of psychedelics by a small number of companies may stifle innovation and reduce access to these therapies. 11, 2021), [link] [ [link] ]; Danielle Schlosser & Thomas R.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. March 8, 2021). The federal government and most of the states in the U.S. Id ; 21 CFR 312.1-10;

Law 105

Law Therapy Clinical Trials Research and Development 105

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In May 2021, a Nature Medicine study showed the benefits of MDMA in relieving post-traumatic stress disorder. [4] 5] The Journal of the American Medical Association published similar findings in May 2021. [6].

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JULY 1, 2021

Launched in summer 2021 with a generous grant from the Saisei Foundation, the Project on Psychedelics Law and Regulation (POPLAR) at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School will advance evidence-based psychedelics law and policy. The Role of Psychedelics in Healing Trauma.

Law 59

Law Policy Research and Development Clinical Trials 59

Cannabis Law Report

OCTOBER 4, 2021

September 30, 2021. A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. Accordingly, it cannot be prescribed by a physician and it is not legally accessible to those who might benefit from it as a therapeutic treatment.

Therapy 52

Therapy Patients Law Clinical Trials 52

Cannabis Law Report

JUNE 8, 2021

Englewood Cliffs, NJ, June 08, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. About Silo Pharma.

Patients 92

Patients Research and Development Clinical Trials Chronic Pain 92

The Cannigma

AUGUST 26, 2021

The country legalized medical cannabis in 2016, but patients in the country have long criticized the program as too restrictive, and access to cannabis-based medicines remains behind that of many other legal cannabis jurisdictions. This also means that the TGA has not accessed these medicines for their safety, quality, or effectiveness.

Legalization 52

Legalization Access Medicine Clinical Trials 52

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1). Nov 24 2021.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

FEBRUARY 10, 2022

Despite Petitioners’ noble cause, the case turned on a technicality after the Court determined that the DEA’s letter stating that such psilocybin treatment was not allowed, the document that prompted the lawsuit, was not a “final” decision of the Attorney General that the Court had jurisdiction to review. Background. Psilocybin. The RTT Act.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Cannabis Law Report

SEPTEMBER 20, 2021

KWC is a limited liability corporation formed under the laws of Arizona , which operates 10 ketamine infusion treatment clinics, across Arizona , Colorado , Florida , Illinois , Minnesota , Nevada , Texas , and Washington. Transaction Highlights.

Treatment 52

Treatment Media Research and Development Patients 52

Cannabis Law Report

NOVEMBER 16, 2021

Our treatment designed for delaying aging has a distinctive drug profile of oral delivery, selectivity, and very low toxicity as compared with TNF blockers, all of which are delivered by injection only. “For 3 Nature Aging | VOL 1 | July 2021 | p. President, Director and Chief Medical Officer of MyMD.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 14, 2021

13, 2021 /PRNewswire-PRWeb/ — A host of scientific research and clinical trials around the world are affirming the remarkable effectiveness of psilocybin, the principal psychoactive component of “magic mushrooms,” in the treatment of a variety of medical conditions, including depression, anxiety, addiction, and PTSD.

Clinical Trials 52

Clinical Trials Events Medicine Therapy 52

Healer

MARCH 26, 2021

March 19, 2021. Gresh has joined a growing number of patients who swear by medical cannabis not only as a treatment option for chronic pain, but also as a substitute for prescription opioids used in pain management. Some researchers believe cannabis can help wean prescription opioid users off the addictive and potentially deadly drugs.

Chronic Pain 86

Chronic Pain Clinical Trials Treatment Patients 86

Cannabis Law Report

JANUARY 5, 2022

“This patent issuance is rewarding and timely as we launch our Phase 2 trial of MYMD-1 as a therapy for sarcopenia, frailty, and aging, which is currently recruiting patients,” said Chris Chapman, M.D., President, Director and Chief Medical Officer of MyMD. 2 Goates et al. 3 Koon Yee-Lee et al. 4 [link].

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

JULY 6, 2021

July 06, 2021 08:30 ET | Source: Ehave. MIAMI, July 06, 2021 (GLOBE NEWSWIRE) — Ehave, Inc., (OTC Dr. Bankole Johnson was featured in a March 5 th 2021 Forbes article, “Dr. We look forward to Dr. Johnson’s expertise as we expand our mental health analytical platform and enter clinical trials.”

Research and Development 97

Research and Development Wellness and Beauty Clinical Trials Therapy 97

Cannabis Law Report

NOVEMBER 23, 2021

It’s also important to note that MYMD-1 shows promise in pre-clinical studies as a treatment for immune diseases including rheumatoid arthritis, multiple sclerosis, and Hashimoto’s thyroiditis, and as an anti-fibrotic and anti-proliferation therapeutic.”.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Veriheal

MARCH 23, 2023

The people of Japan, a country renowned for its sushi cuisine scene, iconic Mount Fuji, and eye-catching cherry blossom trees, may soon have access to legal medicinal marijuana for intractable diseases. On Tuesday, January 24, several legislative bills were unveiled by the Japanese government.

Legalization 66

Legalization Marijuana Clinical Trials Seed-To-Sale 66

Cannabis Law Report

JUNE 1, 2021

Company remains on track for potential approval of Vicineum™ in the US in August 2021. Steve Barbera to Vice President, Market Access. In prior clinical trials conducted by Sesen Bio, EpCAM has been shown to be overexpressed in NMIBC cells with minimal to no EpCAM expression observed on normal bladder cells.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Canna Care Docs

DECEMBER 16, 2020

It would feel like an out-of-body experience, except for one fact: your body is constantly reminding you of those symptoms you’ve been suffering from all this time, putting treatment on the back burner while you deal with life as we know it. Could medical cannabis help you find the “new you” in 2021? Enough is enough. Chronic pain.

Chronic Pain 52

Chronic Pain Marijuana Clinical Trials Epilepsy 52

Veriheal

MAY 12, 2021

The relationship between cannabis and cancer has long been at the forefront of research regarding its medical efficacy, mainly for legalization and treatment purposes. The study was conducted by Matthew Cousins, Mary Jannausch, Reshma Jagsi, and Mark IIgen and was published on March 16, 2021.

Patients 98

Patients Consumption Clinical Trials Education 98

Cannabis Law Report

JULY 14, 2021

(“ImmunoFlex” ), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. ImmunoFlex’s believes that the immune system changes observed in this clinical study are beneficial changes with the potential to improve immune system competence.

Research and Development 105

Research and Development Clinical Trials Events Treatment 105